Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Axonics, Inc. (AXNX)
|
Add to portfolio |
|
|
Price: |
$58.61
| | Metrics |
OS: |
50.0
|
M
| |
-5
|
% ROE
|
Market cap: |
$2.93
|
B
| |
-8
|
% ROIC
|
Net cash:
|
$332
|
M
| |
$6.64
|
per share
|
EV:
|
$2.6
|
B
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
($18.4)
|
M
| |
|
|
EPS |
($0.67)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
Revenues | 273.7 | 180.3 | 111.5 | 13.8 | 0.7 | 0.1 | 0.0 |
Revenue growth | 51.8% | 61.6% | 707.1% | 1854.7% | 452.3% | | |
Cost of goods sold | 76.0 | 64.6 | 44.4 | 6.5 | 0.4 | 0.1 | 0.0 |
Gross profit | 197.7 | 115.7 | 67.1 | 7.3 | 0.4 | 0.0 | 0.0 |
Gross margin | 72.2% | 64.2% | 60.2% | 53.0% | 49.6% | 7.8% | |
Sales and marketing | 156.0 | 105.8 | 66.1 | 48.7 | 3.7 | 1.0 | 0.5 |
Research and development | 34.4 | 37.3 | 29.1 | 20.1 | 19.4 | 12.3 | 12.5 |
General and administrative | 40.2 | 30.0 | 25.6 | 19.1 | 9.4 | 4.8 | 4.5 |
EBITA | -33.1 | -57.6 | -53.7 | -80.5 | -32.0 | -18.1 | -17.5 |
EBITA margin | -12.1% | -31.9% | -48.2% | -582.4% | -4531.4% | -14171.1% | |
Amortization of intangibles | 9.4 | 7.2 | 0.1 | 0.1 | 0.1 | 0.1 | |
EBIT | -42.5 | -64.8 | -53.8 | -80.6 | -32.1 | -18.2 | -17.5 |
EBIT margin | -15.5% | -36.0% | -48.3% | -583.2% | -4545.5% | -14249.2% | |
Pre-tax income | -62.3 | -79.3 | -54.9 | -79.9 | -32.5 | -18.1 | -17.4 |
Income taxes | -2.6 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | 4.2% | | | | | | 0.0% |
Net income | -59.7 | -80.1 | -54.9 | -79.9 | -32.5 | -18.1 | -17.4 |
Net margin | -21.8% | -44.4% | -49.2% | -578.4% | -4594.5% | -14110.2% | |
|
Diluted EPS | ($1.28) | ($1.86) | ($1.48) | ($2.80) | ($4.64) | ($7.04) | ($7.52) |
Shares outstanding (diluted) | 46.7 | 43.1 | 37.0 | 28.6 | 7.0 | 2.6 | 2.3 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|